Provided by Tiger Fintech (Singapore) Pte. Ltd.

Takeda Pharmaceutical Co Ltd

15.05
-0.0900-0.59%
Post-market: 15.050.00000.00%18:02 EDT
Volume:935.36K
Turnover:14.07M
Market Cap:46.04B
PE:36.36
High:15.12
Open:15.12
Low:14.89
Close:15.14
Loading ...

Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?

Insider Monkey
·
16 Feb

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

Zacks
·
14 Feb

ADMA Loses 8.9% in a Month: How Should You Play the Stock?

Zacks
·
08 Feb

Takeda Pharmaceutical Names Julie Kim Chief Executive

MT Newswires Live
·
30 Jan

Takeda CEO Christophe Weber to retire in 2026, Julie Kim to succeed

TIPRANKS
·
30 Jan

Takeda Pharmaceutical Fiscal Q3 Core Earnings Decline, Revenue Rises

MT Newswires Live
·
30 Jan

Takeda FY2024 Guidance Raised: Core Revenue And Profit Now Expected To Grow Low Single Digits; Core EPS Revised To Flat/Slight Decline. Free Cash Flow Raised To ¥550B–¥650B.

Benzinga
·
30 Jan

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

Business Wire
·
30 Jan

Takeda Pharmaceutical Q3 2024 GAAP EPS ¥15.01 Down From ¥67.38 YoY, Sales ¥1.144T Beat ¥1.139T Estimate

Benzinga
·
30 Jan

Press Release: Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

Dow Jones
·
30 Jan

Takeda Pharmaceutical Says Hema-Quebec to Cover HyQvia for Immunodeficiency Treatment

MT Newswires Live
·
29 Jan

Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age

CNW Group
·
29 Jan

Takeda Pharmaceutical Expected to Post Lower Third-Quarter Net Profit -- Earnings Preview

Dow Jones
·
29 Jan

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

Benzinga
·
28 Jan

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

Dow Jones
·
28 Jan

Neurocrine Amends Collaboration with Takeda on Osavampator

MT Newswires Live
·
28 Jan